Skip to main content
Top
Published in: Cardiovascular Toxicology 3/2017

01-07-2017

Dofetilide in Overdose: A Case Series from Poison Center Data

Authors: M. A. Hieger, K. F. Maskell, M. J. Moss, S. W. Powell, K. L. Cumpston

Published in: Cardiovascular Toxicology | Issue 3/2017

Login to get access

Abstract

Dofetilide is a class III antiarrhythmic used for treating atrial dysrhythmias. Though its adverse effects are well described in routine use, very little is known about dofetilide toxicity in overdose. This is a retrospective case series of consecutive patients reported to our poison center after dofetilide overdose. Twenty-seven cases were included. Seventeen patients were treated at a healthcare facility, and of these, eight were admitted. Twenty-one patients took one extra capsule, four took someone else’s medication, one took three extra capsules, and one had a large intentional overdose. Ten patients had co-ingestants reported, including three QT-prolonging agents. No one required cardioversion, defibrillation, CPR, or overdrive pacing. The patient who reported taking 90 times his usual dose in suicide attempt was the only patient to have significant clinical effects. He experienced an 8-beat run of non-sustained ventricular tachycardia, frequent multifocal PVCs, and ventricular bigeminy. He received magnesium sulfate and potassium chloride supplementation. In this series, unintentional small overdoses did not result in significant clinical effects and were often managed successfully at home, despite the fact that information showing a single capsule can cause torsades. This study is limited by its small sample size, retrospective design, and reliance on incomplete information.
Literature
1.
go back to reference Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., et al. (1991). UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. Journal of Pharmacology and Experimental Therapeutics, 256(1), 318–324.PubMed Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., et al. (1991). UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. Journal of Pharmacology and Experimental Therapeutics, 256(1), 318–324.PubMed
2.
go back to reference Aktas, M. K., Shah, A. H., & Akiyama, T. (2007). Dofetilide-induced long QT and torsades de pointes. Annals Noninvasive Electrocardiology, 12(3), 197–202.CrossRef Aktas, M. K., Shah, A. H., & Akiyama, T. (2007). Dofetilide-induced long QT and torsades de pointes. Annals Noninvasive Electrocardiology, 12(3), 197–202.CrossRef
5.
go back to reference Mounsey, J. P., & DiMarco, J. P. (2000). Cardiovascular drugs. Dofetilide. Circulation, 102(21), 2665–2670.CrossRefPubMed Mounsey, J. P., & DiMarco, J. P. (2000). Cardiovascular drugs. Dofetilide. Circulation, 102(21), 2665–2670.CrossRefPubMed
6.
go back to reference Falk, R. H., & Decara, J. M. (2000). Dofetilide: A new pure class III antiarrhythmic agent. American Heart Journal, 140(5), 697–706.CrossRefPubMed Falk, R. H., & Decara, J. M. (2000). Dofetilide: A new pure class III antiarrhythmic agent. American Heart Journal, 140(5), 697–706.CrossRefPubMed
7.
Metadata
Title
Dofetilide in Overdose: A Case Series from Poison Center Data
Authors
M. A. Hieger
K. F. Maskell
M. J. Moss
S. W. Powell
K. L. Cumpston
Publication date
01-07-2017
Publisher
Springer US
Published in
Cardiovascular Toxicology / Issue 3/2017
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-016-9384-9

Other articles of this Issue 3/2017

Cardiovascular Toxicology 3/2017 Go to the issue